No increase in acute hepatitis of unspecified etiology, adenovirus types 40/41 above prepandemic baseline levels.
One more US death related to pediatric hepatitis was reported.
Pharmacotherapy for alcohol use disorder linked to reduced incidence of hepatic decompensation in patients with cirrhosis.
CDC updates hepatitis B vaccination recommendation for adults
In this study, researchers assessed the nationwide rate of testing and treatment initiations for hepatitis C virus infection in the United States following the onset of the COVID-19 pandemic through the end of 2020.
Incidence of overall mortality was also highest for untreated patients with hepatitis C virus.
The 2022 adult immunization schedule summarizes ACIP recommendations, including several changes.
Investigators assessed the manufacturing consistency, safety, and efficacy of a 3-antigen hepatitis B vaccine vs a single-antigen formulation.
People with hepatitis C are at an increased risk for several autoimmune disorders. Researchers sought to discover a link between the virus and hypothyroidism.
Atypical celiac disease may present as dermatitis herpetiformis, anemia, elevated transaminases, short stature, and osteopenia/osteoporosis.
The COVID-19 pandemic and opioid crisis created new barriers to HCV treatment, leading to the lowest annual treatment rate in 5 years.
November and December 2021 FDA drug approvals include treatments for hepatitis B, achondroplasia, cancer, and polycythemia vera.
Until now, the shots were recommended only for certain groups of adults.
Investigators assessed the factors associated with medication treatment for opioid use disorder and whether it is linked to hepatic decompensation or death in patients with cirrhosis and active opioid use disorder.
The natural history of cirrhosis is significantly affected by the increasing prevalence of infections, with strategies for prevention and treatment difficult to compose.
Researchers summarized the reciprocal interaction between sleep and liver diseases, including cirrhosis, and investigated potential approaches for therapeutic interventions.
Epstein-Barr virus infection may present with liver injury characterized by acute cholestatic hepatitis, as demonstrated in this case.
Although NASH is a common cause of chronic liver disease, there is limited evidence surrounding its management.
Researchers studied the impact of current opioid agonist therapy on initiation of chronic hepatitis C virus treatment among a population of individuals who inject drugs.
Needs assessment survey conducted in response to increasing clinical burden of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis